Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

16.33USD
22 May 2018
Change (% chg)

$0.30 (+1.87%)
Prev Close
$16.02
Open
$16.30
Day's High
$16.80
Day's Low
$15.77
Volume
73,553
Avg. Vol
253,223
52-wk High
$22.70
52-wk Low
$4.55

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
Monday, 2 Apr 2018 08:15am EDT 

April 2 (Reuters) - Abeona Therapeutics Inc ::APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER.  Full Article

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
Monday, 2 Apr 2018 08:15am EDT 

April 2 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIM MILLER CONTINUES AS PRESIDENT AND ASSUMES CHIEF SCIENTIFIC OFFICER ROLE.THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC.  Full Article

Abeona Therapeutics Reports Q4 Loss Per Share $0.19
Friday, 16 Mar 2018 05:09pm EDT 

March 16 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q4 LOSS PER SHARE $0.19.Q4 REVENUE $215,000 VERSUS I/B/E/S VIEW $244,000.Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease
Thursday, 15 Mar 2018 08:45am EDT 

March 15 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE.ABEONA THERAPEUTICS - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 PROGRAM, AN AAV-BASED GENE THERAPY FOR TREATMENT OF CLN1 DISEASE.  Full Article

Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns
Monday, 12 Feb 2018 08:45am EST 

Feb 12 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE.ABEONA THERAPEUTICS INC - ABO-202 IS ANTICIPATED TO ENTER CLINICAL TRIALS IN 2018.  Full Article

Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder
Monday, 29 Jan 2018 08:45am EST 

Jan 29 (Reuters) - Abeona Therapeutics Inc ::ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA.ABEONA THERAPEUTICS - CONTINUES TO ENGAGE FDA ON ITS PIVOTAL PHASE 3 CLINICAL TRIAL DESIGN, AND WILL PROVIDE AN UPDATE ON RMAT PROGRAM IN COMING MONTHS.  Full Article

Abeona Q3 loss per share $0.13
Wednesday, 15 Nov 2017 08:25am EST 

Nov 15 (Reuters) - Abeona Therapeutics Inc :Abeona reports third quarter 2017 financial results and recent business highlights.Q3 loss per share $0.13.Q3 revenue $219,000 versus I/B/E/S view $220,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Abeona Therapeutics announces public offering of common stock
Monday, 16 Oct 2017 04:01pm EDT 

Oct 17 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces public offering of common stock.  Full Article

Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​
Monday, 16 Oct 2017 08:26am EDT 

Oct 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​.  Full Article

Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA
Wednesday, 11 Oct 2017 08:19am EDT 

Oct 11 (Reuters) - Abeona Therapeutics Inc : :Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA.Says to ‍report additional clinical data in ABO-102 global trial later this year​.  Full Article

BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial

* ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING